Success Story

CAR-T startup Vittoria Biotherapeutics launches

Vittoria Biotherapeutics‘ mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies to create new therapies that address unmet clinical needs.

The technology the company is attempting to commercialize was developed by Dr. Marco Ruella, a hematologist from Italy who came to the United States 10 years ago to study under Penn CAR T-cell pioneers Dr. Carl June and Saar Gill.

Ruella, Vittoria’s scientific founder, is an assistant professor of medicine at the Center for Cellular Immunotherapies at Penn’s Perelman School of Medicine. He is also scientific director of the lymphoma program at the Hospital of the University of Pennsylvania.

Skip to content